Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Vulvovaginal Candidiasis - Pipeline Review, H2 2016


  • Products Id :- GMDHC8459IDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Vulvovaginal Candidiasis - Pipeline Review, H2 2016', provides an overview of the Vulvovaginal Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis

- The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects

- The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Vulvovaginal Candidiasis Overview 7

Therapeutics Development 8

Pipeline Products for Vulvovaginal Candidiasis - Overview 8

Vulvovaginal Candidiasis - Therapeutics under Development by Companies 9

Vulvovaginal Candidiasis - Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

Vulvovaginal Candidiasis - Products under Development by Companies 13

Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 14

Cidara Therapeutics, Inc. 14

Grupo Ferrer Internacional, S.A. 15

NovaDigm Therapeutics, Inc. 16

Scynexis, Inc. 17

TGV-Laboratories 18

Viamet Pharmaceuticals, Inc. 19

Vulvovaginal Candidiasis - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Combination Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

(clotrimazole + diclofenac sodium) - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

arasertaconazole - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CD-101 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

MH-010 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Myc-102 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

NDV-3 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

NDV-3A - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SCY-078 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TOL-463 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

VT-1161 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Vulvovaginal Candidiasis - Dormant Projects 48

Vulvovaginal Candidiasis - Discontinued Products 49

Vulvovaginal Candidiasis - Product Development Milestones 50

Featured News & Press Releases 50

Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis 50

Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 51

Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting 51

Aug 08, 2016: SCYNEXIS Reports Second Quarter 2016 Financial Results and Provides Company Update 52

Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis 53

Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 54

Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors 55

May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate 56

Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis 57

Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 58

Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV 59

Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis 59

Jul 29, 2015: Viamet to Present at Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 60

Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015 60

Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 22

Number of Products by Stage and Targets, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

List of Tables

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Comparative Analysis by Unknown Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Vulvovaginal Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016 14

Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 15

Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016 16

Vulvovaginal Candidiasis - Pipeline by Scynexis, Inc., H2 2016 17

Vulvovaginal Candidiasis - Pipeline by TGV-Laboratories, H2 2016 18

Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Assessment by Combination Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Vulvovaginal Candidiasis - Dormant Projects, H2 2016 48

Vulvovaginal Candidiasis - Discontinued Products, H2 2016 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Cidara Therapeutics, Inc.

Grupo Ferrer Internacional, S.A.

NovaDigm Therapeutics, Inc.

Scynexis, Inc.

TGV-Laboratories

Viamet Pharmaceuticals, Inc.

Vulvovaginal Candidiasis Therapeutic Products under Development, Key Players in Vulvovaginal Candidiasis Therapeutics, Vulvovaginal Candidiasis Pipeline Overview, Vulvovaginal Candidiasis Pipeline, Vulvovaginal Candidiasis Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com